SemBioSys appoints new board member



    CALGARY, May 7 /CNW/ - SemBioSys Genetics Inc. (TSX:SBS), specializing in
the manufacture of high-value proteins and oils in plant seeds, held its
Annual and Special Meeting of Shareholders on May 5th, 2009 at its corporate
headquarters in Calgary, Alberta.
    At the Meeting the shareholders re-elected Mr. Richard Smith, Mr. Ian S.
Brown, Dr. Alexander R. Giaquinto and Dr. Oye Olukotun, and elected Mr.
William H. Smith, Q.C. to serve as Directors of the Company. Mr. James Szarko,
CA was appointed to the Board in January, when he was appointed President and
CEO of SemBioSys.
    William (Bill) Smith, Q.C., has been involved in the start up or initial
phases of more than 30 companies in a variety of industries, working with
senior executives and Boards. He has been a director of numerous public and
significant private business organizations. Bill has practiced law for more
than 30 years, including more than 20 years in the Calgary Business Law Group
of McCarthy Tetrault LLP. Mr. Smith served as acting Chief Executive Officer
of the Alberta Securities Commission and chaired the Alberta Securities
Commission, Securities Advisory Committee from its inception for 10 years. In
January 2000, he was appointed as Queen's Counsel in recognition of his
community activities.

    About SemBioSys

    Calgary, Alberta-based SemBioSys is a world leader in manufacturing
high-value proteins and oils in plant seeds. With its unique, proprietary
platform, SemBioSys provides partners with product enablement, exceptionally
low cost and unprecedented scalability. The Company applies this platform with
high selectivity to opportunities where it has a unique competitive advantage.
Since its inception, SemBioSys has produced more than 50 non-native proteins
and oils using its patented seed technology, demonstrating applicability
across a broad range of industries such as pharmaceuticals, personal care and
industrial products. The Company's current pharmaceutical development programs
include insulin (SBS-1000, regulated as a biosimilar in Europe) and Apo
AIMilano, a next-generation cardiovascular therapy. SemBioSys is listed on the
Toronto Stock Exchange under the ticker SBS. More information is available at
www.sembiosys.com.

    This press release contains certain forward-looking statements,
including, without limitation, statements containing the words "believe",
"may", "plan", "will", "estimate", "continue", "anticipate", "intend",
"expect" and other similar expressions which constitute "forward-looking
information" within the meaning of applicable securities laws. Forward-looking
statements reflect the Company's current expectation and assumptions, and are
subject to a number of risks and uncertainties that could cause actual results
to differ materially from those anticipated. These forward-looking statements
involve risks and uncertainties including, but not limited to, changing market
conditions and market size, the acceptance of an IND by the FDA in respect of
clinical studies, the submission of a CTA to the appropriate European
authorities, the successful initiation and timely and successful completion of
clinical studies, the fact that Apo AIMilano is currently a development stage
drug, the establishment of corporate alliances, the impact of competitive
products and pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time-to-time in the
Company's ongoing filings with the Canadian securities regulatory authorities
which filings can be found at www.sedar.com. Given these risks and
uncertainties, readers are cautioned not to place undue reliance on such
forward-looking statements. The Company undertakes no obligation to publicly
update or revise any forward-looking statements either as a result of new
information, future events or otherwise, except as required by applicable
Canadian securities laws.



    %SEDAR: 00020947E




For further information:

For further information: SemBioSys Genetics Inc., Abby Garfunkel,
Investor Relations, Phone: (403) 717-4185, E-mail: garfunkela@sembiosys.com;
The Trout Group, Christine Labaree, Managing Director, Phone: (617) 583-1307, 
E-mail: clabaree@troutgroup.com, The Equicom Group Inc., Ross Marshall, Vice
President, Phone: (416) 815-0700 ext. 238, E-mail: rmarshall@equicomgroup.com

Organization Profile

SemBioSys Genetics Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890